Private Advisory Group’s TG Therapeutics TGTX Stock Holding History

Private Advisory Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-20,659	Closed	-$240K	–	150
2017 Q1	$240K	Buy	+20,659	New	+$148K	0.16%	125

Other funds holding TGTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Private Advisory Group's TGTX Position: Q2 2017 in Review

Private Advisory Group sold out of TG Therapeutics (TGTX) in Q2 2017, closing a stake of 20,659 shares — an estimated $240K sold.

Private Advisory Group first reported a position in TGTX in Q1 2017 and held it in 1 quarter. The position peaked at $240K in Q1 2017. 106 funds tracked by Wall St. Rank hold TGTX as of Q2 2017.

Private Advisory Group reported no remaining TG Therapeutics position as of Q2 2017 after selling out during the quarter.
Private Advisory Group sold 20,659 TG Therapeutics shares in Q2 2017, an estimated $240K.
Private Advisory Group first reported a position in TG Therapeutics in Q1 2017 and held it in 1 quarter.
Private Advisory Group's TG Therapeutics position peaked at $240K in Q1 2017.
106 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2017.

Based on Private Advisory Group's 13F filing for Q2 2017, filed 15 Aug 2017.